United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - cefuroxime axetil tablets, usp are indicated for the treatment of adult patients and pediatric patients (13 years and older) with mild-to-moderate pharyngitis/tonsillitis caused by susceptible strains of streptococcus pyogenes . limitations of use cefuroxime axetil tablets, usp are indicated for the treatment of pediatric patients (who can swallow tablets whole) with acute bacterial otitis media caused by susceptible strains of streptococcus  pneumoniae , haemophilus influenzae (including β- lactamase-producing strains), moraxella catarrhalis (including β- lactamase-producing strains), or streptococcus pyogenes. cefuroxime axetil tablets, usp are indicated for the treatment of adult and pediatric patients (13 years and older) with mild-to-moderate acute bacterial maxillary sinusitis caused by susceptible strains of streptococcus pneumoniae or haemophilus influenzae (non- β-lactamase-producing strains only). limitations of use the effectiveness of cefuroxime axetil tablets, usp for sinus infections caused

Malta - English - Medicines Authority

dr. friedrich eberth arzneimittel gmbh am bahnhof 2, ursensollen 92289, germany - cefuroxime sodium - powder for solution for infusion or injection - cefuroxime sodium 750 mg - antibacterials for systemic use

Malta - English - Medicines Authority

dr. friedrich eberth arzneimittel gmbh am bahnhof 2, ursensollen 92289, germany - cefuroxime sodium - powder for solution for infusion or injection - cefuroxime sodium 1500 mg - antibacterials for systemic use

United States - English - NLM (National Library of Medicine)

wg critical care, llc - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 750 mg - cefuroxime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - meningitis

United States - English - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 125 mg in 5 ml - note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bioequivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. the safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well-controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen. - pharyngitis/tonsillitis caused by streptococcus pyogenes. note: the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. cefuroxime axetil for oral suspensio

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cefuroxime sodium 1578mg equivalent to cefuroxime 1500 mg;   - powder for injection - 1.5 g - active: cefuroxime sodium 1578mg equivalent to cefuroxime 1500 mg   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include:

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - cefuroxime sodium 789mg equivalent to cefuroxime 750 mg;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to cefuroxime 750 mg   - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include:

United States - English - NLM (National Library of Medicine)

direct rx - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology). cefuroxime axetil tablets cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   - pharyngitis/tonsillitis caused by streptococcus pyoge

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology).   cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   1.    pharyngitis/tonsillitis caused

United States - English - NLM (National Library of Medicine)

rebel distributors corp - cefuroxime axetil (unii: z49qdt0j8z) (cefuroxime - unii:o1r9fj93ed) - cefuroxime axetil 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   note: cefuroxime axetil tablets and cefuroxime axetil for oral suspension are not bio­equivalent and are not substitutable on a milligram-per-milligram basis (see clinical pharmacology).   cefuroxime axetil tablets: cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below:   1.    pharyngitis/tonsillitis caused by streptococcus pyogenes.